Los Angeles Capital Management LLC Has $1.08 Million Stake in Surmodics, Inc. (NASDAQ:SRDX)

Los Angeles Capital Management LLC reduced its stake in Surmodics, Inc. (NASDAQ:SRDX) by 23.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 27,950 shares of the company’s stock after selling 8,475 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.20% of Surmodics worth $1,084,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. Acadian Asset Management LLC lifted its stake in shares of Surmodics by 11.3% in the first quarter. Acadian Asset Management LLC now owns 408,779 shares of the company’s stock worth $11,988,000 after buying an additional 41,617 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Surmodics by 5.0% during the second quarter. Renaissance Technologies LLC now owns 606,538 shares of the company’s stock valued at $25,499,000 after acquiring an additional 28,990 shares during the period. Gardner Lewis Asset Management L P acquired a new stake in shares of Surmodics in the second quarter valued at about $8,531,000. Sagefield Capital LP bought a new position in shares of Surmodics in the second quarter worth about $2,350,000. Finally, Trium Capital LLP acquired a new position in shares of Surmodics during the 2nd quarter worth about $1,406,000. Institutional investors own 96.63% of the company’s stock.

Surmodics Stock Performance

SRDX opened at $38.09 on Friday. The stock’s 50 day simple moving average is $38.51 and its 200-day simple moving average is $39.02. The company has a current ratio of 3.98, a quick ratio of 3.22 and a debt-to-equity ratio of 0.25. The stock has a market cap of $543.54 million, a PE ratio of -47.02 and a beta of 1.20. Surmodics, Inc. has a 1 year low of $25.17 and a 1 year high of $42.44.

Surmodics (NASDAQ:SRDX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.14. Surmodics had a negative net margin of 9.15% and a negative return on equity of 3.77%. The company had revenue of $33.23 million during the quarter, compared to the consensus estimate of $30.69 million. Sell-side analysts forecast that Surmodics, Inc. will post 0.17 EPS for the current year.

Analyst Upgrades and Downgrades

SRDX has been the topic of a number of research analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Surmodics in a report on Thursday, November 7th. StockNews.com assumed coverage on shares of Surmodics in a research note on Friday. They set a “hold” rating for the company. Five analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $50.00.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).